• NASH & Diabetes
    • S1-E1 – Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics
      • S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients
      • S3-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance
  • NASH Tsunami
    • Season 3 (2022)
    • Season 2 (2021)
      • Year In Review 2021
    • Season 1 (2020)
      • Year In Review 2020
    • Most Popular Episodes
  • Events
    • 2021 Events
      • AASLD TLMdX 2021
      • EASl ILC 2021
      • NASH-TAG 2021
  • Sponsorships
    • Our Sponsors & Affiliates
    • Sponsorship Programs
  • Surfers
  • Contact
Menu
  • NASH & Diabetes
    • S1-E1 – Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics
      • S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients
      • S3-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance
  • NASH Tsunami
    • Season 3 (2022)
    • Season 2 (2021)
      • Year In Review 2021
    • Season 1 (2020)
      • Year In Review 2020
    • Most Popular Episodes
  • Events
    • 2021 Events
      • AASLD TLMdX 2021
      • EASl ILC 2021
      • NASH-TAG 2021
  • Sponsorships
    • Our Sponsors & Affiliates
    • Sponsorship Programs
  • Surfers
  • Contact
Bars

Sponsor

Discussion Group

Join The Discussion in our LinkedIn or Facebook Discussion Groups

Facebook Linkedin

Join The Live Recordings

Recording for this session will take place at 3:15p Eastern US time (1900H CET, 1800H BT) on Monday.

Register For Next Recording
Copyright © SurfingNASH.Com 2022
Linkedin Facebook Twitter Instagram
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
Stay In Touch
Apple Spotify Youtube
Menu
  • NASH & Diabetes
    • S1-E1 – Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics
      • S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients
      • S3-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance
  • NASH Tsunami
    • Season 3 (2022)
    • Season 2 (2021)
      • Year In Review 2021
    • Season 1 (2020)
      • Year In Review 2020
    • Most Popular Episodes
  • Events
    • 2021 Events
      • AASLD TLMdX 2021
      • EASl ILC 2021
      • NASH-TAG 2021
  • Sponsorships
    • Our Sponsors & Affiliates
    • Sponsorship Programs
  • Surfers
  • Contact

Join The Discussion…

Invite Request
Apple Spotify Youtube Soundcloud

NASH & Diabetes Podcast and NASH Tsunami Podcast

S3-E1.2 - NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance

S3-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance

Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among

Learn More »
S3-E101.1 - Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients

S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients

Hepatology Researcher and Key Opinion Leader Stephen Harrison discussed results of his 2021 publication in the Journal of Hepatology that

Learn More »
S1-E1 - New Podcast: Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics

S1-E1 – New Podcast: Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics

In this Premier episode of The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide, key opinion leaders Doctors

Learn More »
  • June 30, 2022

S3-E34 – #ILC2022 Wrap-Up 1: NASH Drug Development Excitement!

  • June 29, 2022

S3-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance

  • June 28, 2022

S3-E33 – Day 4 of ILC2022: Friendly debates about NITs and the Patient Advocate’s Perspective

  • June 26, 2022

S3-E32 – Days 1 — 3 of ILC 2022: The Value of FIB-4 and In-Person Meetings

  • June 21, 2022

S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients

  • June 19, 2022

S3-E30.4 – Highlighting Intriguing ILC2022 Abstracts: Potential Uses of FIB-4

  • June 19, 2022

S3-E30.3 – Highlighting Intriguing ILC2022 Abstracts: More on NAFLD Quality of Life

  • June 18, 2022

S3-E30.2 – Highlighting Intriguing ILC2022 Abstracts: Elastography and the Importance of NAFLD Quality-of-Life Metrics

  • June 18, 2022

S3-E30.1 – Highlighting Intriguing ILC2022 Abstracts: Machine Learning Identified NASH Biomarkers and a Cost-Effectiveness Study

  • June 15, 2022

S3-E30 – Previewing #ILC2022: Focus on NITs and Patients

More Episodes